12.16.13
The year of the shuffle continues at Cambridge, Mass.-based InVivo Therapeutics Corporation. As previously announced, Chief Financial Officer Gregory Perry will leave the company at the end of the year to join another local biotechnology company as its new chief financial and business officer. Replacing him on Dec. 31 will be Steven McAllister acting as interim chief financial officer.
McAllister served as vice president of finance and administration for Biomet Spine and Bone Healing Technologies from 2007 to 2013. Between 1999 and 2007 he served DePuy Inc. in several capacities including director of finance, worldwide operations. Before DePuy, he worked for Howmedica, a Pfizer subsidiary that was sold to Stryker in 1998.
“Steve McAllister brings expertise in both finance and in the operations of device companies,” said InVivo’s Interim CEO Michael Astrue. “I am confident that he will provide the same judgment, integrity and strategic vision provided by Greg Perry during our initial repositioning of InVivo.”
InVivo is a biomaterials company that focuses on drug delivery solutions for spinal cord injuries.
McAllister served as vice president of finance and administration for Biomet Spine and Bone Healing Technologies from 2007 to 2013. Between 1999 and 2007 he served DePuy Inc. in several capacities including director of finance, worldwide operations. Before DePuy, he worked for Howmedica, a Pfizer subsidiary that was sold to Stryker in 1998.
“Steve McAllister brings expertise in both finance and in the operations of device companies,” said InVivo’s Interim CEO Michael Astrue. “I am confident that he will provide the same judgment, integrity and strategic vision provided by Greg Perry during our initial repositioning of InVivo.”
InVivo is a biomaterials company that focuses on drug delivery solutions for spinal cord injuries.